344860 — Innogene Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesSpeculativeMicro CapNeutral

Annual income statement for Innogene Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Interim Report	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	—	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	7,181	9,385	9,139	10,101	8,945
Cost of Revenue
Gross Profit	5,367	7,324	6,787	7,329	6,635
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	6,210	6,986	7,652	8,875	8,314
Operating Profit	971	2,399	1,488	1,226	630
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	801	2,436	1,545	1,706	1,123
Provision for Income Taxes
Net Income After Taxes	790	2,258	1,339	1,396	945
Net Income Before Extraordinary Items
Net Income	790	2,258	1,339	1,396	945
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	790	2,258	1,339	1,396	945
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	100	243	144	120	79.6
Dividends per Share